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The glucose-6-phosphatase enzyme protein of the human hepatic microsomal glucose-6-phosphatase syst m was identi- 
fied as a 36.5 kDa polypeptide. The 36.5 kDa glucose-6-phosphatase enzyme protein was shown to be absent in the 
microsomes isolated from a patient previously diagnosed ashaving atype 1 a glycogen storage disease. 
Glucose-6-phosphatase; Glycogen storage disease; Phosphohydrolase; (Liver microsome) 
1. INTRODUCTION 
Hepatic microsomal glucose-6-phosphatase (EC 
3.1.3.9) catalyzes the terminal steps of both gluco- 
neogenesis and glycogenolysis [1]. The biological 
importance of the glucose-6-phosphatase enzyme 
in the control of blood glucose levels is emphasized 
by the debilitating effects of both its complete 
absence in patients with type la glycogen storage 
disease [2-4] and the abnormally high levels of 
glucose-6-phosphatase andhepatic glucose produc- 
tion in diabetes mellitus [1,5]. Nevertheless virtual- 
ly nothing is known about the human hepatic 
microsomal glucose-6-phosphatase enzyme pro- 
tein. We recently identified the rat hepatic micro- 
somal glucose-6-phosphatase enzyme as a 
36.5 kDa polypeptide by 32p-labelling the 
phosphoryl-enzyme intermediate formed during 
steady-state hydrolysis of glucose 6-phosphate [6]. 
Unfortunately the technique failed to identify the 
human hepatic glucose-6-phosphatase enzyme [6]. 
The human enzyme is much more unstable than the 
rat enzyme [3,6-8] and was completely inactivated 
by the techniques used and no labelled phospho- 
protein was formed. Earlier studies using a variety 
of techniques had reported molecular masses for 
the human hepatic glucose-6-phosphatase enzyme 
of  100, 63, 70 and 58-64 kDa [9-11]. It was 
therefore important for the human hepatic micro- 
somal glucose-6-phosphatase enzyme to be une- 
quivocally identified as a first step in the isolation 
of human DNA probes to allow prenatal diagnosis 
and carrier detection of type la glycogen storage 
disease. 
Here we have used a modified 32p-labelling 
technique and monospecific antibodies to the rat 
hepatic microsomal glucose-6-phosphatase enzyme 
to identify the polypeptide(s) which contain(s) the 
active site of the human hepatic microsomal 
glucose-6-phosphatase enzyme. 
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2. MATERIALS AND METHODS 
Biotinylated anti-sheep antibody, streptavidin-linked p rox- 
idase complex, 32P-labelled tetrasodium pyrophosphate and 
32p-labelled ATP (to prepare 32p-labelled glucose 6-phosphate 
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145 mCi/mmol) were purchased from Amersham (England). 
4-Chloro-l-naphthol, glucose 6-phosphate (monosodium salt), 
mannose 6-phosphate (monosodium salt) were from Sigma 
(Poole, England). Sodium cacodylate also from Sigma was re- 
crystallized from 95% ethanol [12]. The amphoteric detergent 
Empigen BB (alkyl dimethylamine b taine) was the kind gift of 
Albright and Wilson (Whitehaven, England). Lubro112A-9 was 
obtained from 1CI Organics Division (Manchester, England). 
Nitrocellulose was obtained from Schleicher and Schuell 
(Dassel, FRG). All other chemicals were analytical reagent 
grade. 
2.1. Preparation and assays of hepatic microsomes 
Microsomes were prepared from fresh unfrozen human 
hepatic needle or small wedge biopsy samples [3] and livers of 
starved Wistar ats [13] and assayed for glucose-6-phosphatase 
activity as previously described [14]. The type la glycogen 
storage disease patient was a 3-month-old female child which 
was diagnosed on enzymatic analysis of a liver biopsy specimen. 
The glycogen content of the liver was 75 mg/g liver (upper limit 
of normal values is 40 mg/g liver). The activity of the 
glucose-6-phosphatase enzyme in microsomes i olated from the 
liver biopsy specimen was less than 0.01/~mols of inorganic 
phosphate released from glucose 6-phosphate/min per mg 
microsomal protein. The normal range of human hepatic 
glucose-6-phosphatase ctivity is 0.3-0.7/~mol/min per mg 
microsomal protein [3]. Protein concentrations were measured 
by the method of Peterson [15]. Ethical approval for this study 
was given by the Paediatric/Reproductive Medicine Ethics of 
Medical Research Subcommittee of Lothian Health Board and 
the Tayside Health Board Ethical Subcommittee. 
2.2. ~2p-labelling ofglucose-6-phosphatase 
The 32p-labelling of rat and human microsomal 
glucose-6-phosphatase with 32p-labelled glucose 6-phosphate 
and inorganic pyrophosphate was carried out exactly as in [6] 
except for two important changes: (i) prior to incubation the 
microsomes were not fully disrupted with Triton X-100, then 
centrifuged toremove detergent, but were disrupted with 0.5% 
lubrol 12-A9, as described in [5] and immediately added to the 
incubation without centrifugation; (ii) the incubation was car- 
ried out at 0°C for 30 s rather than 30°C for 20 s. 
2.3. SDS-PAGE, autoradiography and immunoblot analysis 
SDS-PAGE and autoradiography were carried out exactly as 
described in [6]. Immunoblot analysis of microsomal samples 
was carried out exactly as described in [16] using sheep anti- 
serum previously shown to be monospecific for the rat hepatic 
microsomal g ucose-6-phosphatase enzyme [6,17]. 
3. RESULTS AND DISCUSSION 
The hepatic microsomal  glucose-6-phosphatase 
is a mul t icomponent  system comprised of  the 
glucose-6-phosphatase enzyme with its active site 
s ituated at the luminal  surface o f  the endoplasmic 
ret iculum membrane,  and a translocase T1, which 
mediates the entry of  glucose 6-phosphate into the 
luminal  compartment .  A second translocase T2 
mediates the equi l ibrat ion of  the product  
phosphate  and the substrate pyrophosphate.  The 
mechanism of  glucose permeat ion across the mem- 
brane has been designated T3 [3,7,16,18]. 
3.1. 32P-labelling o f  the human microsomai 
glucose-6-phosphatase enzyme 
The phosphory l -enzyme intermediate of  the rat 
hepatic glucose-6-phosphatase system formed dur-  
ing steady-state hydrolysis of  glucose 6-phosphate 
has recently been identif ied as a 36.5 kDa polypep- 
t ide [6]. Glucose 6-[32p]phosphate also labelled a 
similar 36.5 kDa polypept ide in rabbit ,  sheep, 
mouse and guinea pig hepatic microsomes [6] but 
fai led to label any polypept ides in human hepatic 
microsomes [6]. The glucose-6-phosphatase en- 
zyme activity f rom human hepatic microsomes is 
known to be more labile than the hepatic enzymes 
f rom other species [3,7,8]. Therefore the most like- 
ly explanat ion for the fai lure to form a phosphoryl -  
enzyme intermediate in human liver was that the 
human enzyme had been inactivated by the tech- 
niques used. The only other protein of  the 
glucose-6-phosphatase system that has been iden- 
t i f ied and puri f ied is T2 [16] and it has the same 
molecular  mass in both rat and human liver [16]. 
However  it could not be assumed that the human 
hepatic glucose-6-phosphatase enzyme was similar 
to the rat enzyme and had a 36.5 kDa polypept ide 
phosphory l -enzyme intermediate,  as several earl ier 
papers had suggested much higher molecular  
masses for the human enzyme of  100, 63, 70 and 
58-64 kDa [11]. 
We therefore studied the effect of  each step in 
the 32p-labelling method on the activity of  the 
human hepatic enzyme. Two steps were found to 
cause inact ivat ion and were modi f ied as described 
in section 2. Lanes 3 and 4 of  fig. 1 show that using 
the modi f ied procedures with 32p-labelled glucose 
6-phosphate a polypept ide was labelled in both rat 
and human microsomes the same result was obtain-  
ed using 32p-labelled pyrophosphate  as substrate 
(not shown). Lanes 3 and 4 o f  fig. 1 were overload- 
ed in terms of  microsomal  protein to determine 
whether any minor  bands were labelled with 32p. 
The over loading of  the gel and the presence of  
glycogen in the samples is the most l ikely cause of  
most  of  the nonspecif ic retention o f  32p at the 
origin (see [6] for a more detai led explanation) as it 
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Fig.l. Immunoblot analysis and autoradiography of 32p_ 
labelled rat and human microsomes. Lanes 1-2 immunoblot 
analysis. Lane 1, 32p-labelled fed rat hepatic microsomes 
(10/~g); lane 2, 32p-labelled human hepatic microsomes 
(11.5/~g). Lanes 3 and 4, an autoradiograph. Lane 3, 32p. 
labelled fed rat hepatic microsomes (100/zg); lane 4, 32p_ 
labelled human hepatic microsomes (104/zg). 
was not ethical to starve human subjects prior to 
biopsy merely to lower the glycogen levels for this 
experiment. 
enzyme protein was also a doublet. The antibody 
used was a sheep anti-rat hepatic microsomal 
glucose-6-phosphatase antiserum which had 
previously been shown to be monospecific for the 
36.5 kDa polypeptide(s) in microsomes isolated 
from rat liver, kidney [6,17] and pancreatic islet 
cells [17]. Lanes 1 and 2 in fig. 1 show that the anti- 
body specifically cross-reacts with a 36.5 kDa poly- 
peptide doublet in both rat and human micro- 
somes. The identification of the immunoreactive 
polypeptide(s) in human microsomes as the 
glucose-6-phosphatase enzyme was confirmed (see 
fig.2, lane 3) by the complete absence of a cross- 
reacting protein in hepatic microsomes isolated 
from a patient previously diagnosed, by conven- 
tional assay methods [14], as having a type la 
glycogen storage disease. The protein identified 
here is clearly different from the 58-64 kDa poly- 
peptide reported by Reczek and Villee [11] in both 
human liver and placenta. It has recently been 
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3.2. Immunodetection f the human hepatic 
glucose-6-phosphatase enzyme 
Previously it had been shown [17] that although 
the 32p-labelled rat protein appears as one band on 
overloaded gels it can be resolved into a doublet on 
very lightly loaded gels [17]. Ten times less 32p_ 
labelled rat and human microsomal protein was 
subjected to immunoblot analysis to determine 
whether or not the human glucose-6-phosphatase 
Fig.2. Immunoblot analysis of human hepatic microsomes. 
Lanes: 1, starved rat liver microsomes (10/zg); 2, control humari 
hepatic microsomes (12/~g); 3,human hepatic microsomes from 
a patient with type la glycogen storage disease (12/zg); 4, 
human hepatic microsomes from a patient with type lb glycogen 
storage disease (13/~g). 
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demonstrated [18] that human placenta does not 
contain the glucose-6-phosphatase enzyme system 
but that it has high levels of nonspecific 
phosphatase activity. The most probable xplana- 
tion is therefore that Reczek and Villee [11] partial- 
ly purified a nonspecific phosphatase from human 
liver obtained from autopsies, as the specific activi- 
ty of glucose-6-phosphatase (0.01 ~mol/min per 
mg) that they reported in frozen adult human 
hepatic microsomes was 50 times lower than the 
levels of glucose-6-phosphatase in fresh adult 
human liver [3]. 
3.3. Conclusions 
The results of the experiments presented here 
establish the identity of the phosphohydrolase 
component of the human hepatic glucose-6-phos- 
phatase system. This conclusion is supported by 
three independent lines of evidence. First, radioac- 
tivity from 32P-labelled glucose 6-phosphate was 
specifically incorporated into the 36.5 kDa poly- 
peptide(s) which correlate(s) exactly with the 
polypeptide(s) previously shown to contain the 
catalytic site of the glucose-6-phosphatase enzyme 
[6] in rat, rabbit, sheep, mouse and guinea pig 
hepatic microsomes [6]. Secondly, the 36.5 kDa 
labelled polypeptide doublet was specifically 
immunostained by antiserum previously shown to 
be monospecific for the rat microsomal glucose-6- 
phosphatase enzyme [17], and able to quantitative- 
ly immunoprecipitate glucose-6-phosphatase c- 
tivity from cholate-solubilized rat hepatic micro- 
somes [6]. Thirdly, the identification of the im- 
munoreactive polypeptide in human hepatic micro- 
somes as the glucose-6-phosphatase enzyme was 
confirmed by the complete absence of a cross- 
reacting protein in human hepatic microsomes 
isolated from a child who had previously been 
shown to have a type la glycogen storage disease 
using conventional ssay methods [14]. 
The identification of the human hepatic micro- 
somal glucose-6-phosphatase enzyme using the 
36.5 kDa polypeptide(s) and the availability of a 
monospecific polyclonal antiserum provide power- 
ful new tools to approach the purification of 
human protein and the isolation of human DNA 
probes for diagnosis, prenatal diagnosis and carrier 
detection of type la glycogen storage diseases. 
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